Lausanne, Switzerland (ots) - - Debiopharm will highlight diversified approaches and commitment to improving outcomes for patients with cancer at the 2023 American Society of Clinical Oncology Conference - A poster presentation and discussion will cover promising interim results with Debio 0123, a potent, highly ...
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
Lausanne, Switzerland (ots/PRNewswire) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and ...
Lausanne, Switzerland (ots) - - Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allowing the pre-identification and treatment of ...
Paris, France and Lausanne Switzerland (ots) - ● The round is co-led by M Ventures and Debiopharm Innovation Fund with Omnes Capital; all joining as new investors ● Series A will enable Iktos to expand its AI technology platform and launch Iktos Robotics; an AI-driven automated end-to-end drug discovery service ...
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
FEI Fédération Equestre Internationale
Cape Town, South Africa and Lausanne, Switzerland (ots/PRNewswire) - Belgium's Ingmar De Vos has been re-elected with an overwhelming majority by the Fédération Equestre Internationale (FEI) member National Federations to serve a third and final term as FEI President. The Presidential election was held during today's FEI Hybrid General Assembly held in Cape Town ...
Boston, USA and Lausanne, Switzerland (ots) - - SaaS Platform Provides Missing Link in Clinical Trial Data Collection, Securely Automating Real-Time Transfer of Up-to-Date Patient Data Directly from EHRs to EDC Systems - Technology Brings New Levels of Speed, Quality and Efficiency to Clinical Trial Data Collection ...
Screeneo Innovation SA; Philipps
Lausanne, Switzerland (ots/PRNewswire) - The Next Evolution in Ultra Short Throw 4K Laser Projection. Philips Projection is pleased to launch the Philips Screeneo U5, its Ultra Short Throw True 4K UHD Laser Projector that offers a 150" (381cm) breathtaking visual experiences from only 16.5 inches (42cm) away. In continuation to the success of the Screeneo U4 UST projector, the company brings the next evolution to the ...
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
Lausanne, Switzerland (ots) - · Currently approved Antibody-Drug Conjugates (ADCs) are large molecules (150 kDa) composed of an antibody, a cytotoxic payload, and a linker connecting the two precedent elements · Debiopharm has launched an ADC Innovation Challenge to a pool of international “problem Solvers” ...
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical ...
Lausanne, Switzerland (ots) - - International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics - The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly ...
Compass Financial Technologies
Lausanne, Switzerland and London (ots/PRNewswire) - Compass Financial Technologies, a Swiss and French based EU regulated index provider and Marex Solutions, Marex's hedging and investment solutions arm that specialises in customised derivative products, collaborate to offer digital asset investment solutions for institutional investors. Marex will leverage the ...
Compass Financial Technologies
Lausanne, Switzerland (ots/PRNewswire) - Compass Financial Technologies, a leading crypto index provider that calculates indices that track over $5bn in assets announces the launch of the Compass Crypto Basket Fundamental DeFi Index (CCBFDEFI) - providing a reliable institutional benchmark to one of the fastest growing sectors in the crypto industry. The CCBFDEFI is ...
Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...
Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...
Lausanne, Switzerland - San Francisco (ots) - Funding to accelerate the development of Mekonos’ System on a Chip (SoC), expand commercial partnerships Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today having invested $4M inMekonos, a biotech company building the future of cell ...
Lausanne, Switzerland / Boston, USA (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical ...
Lausanne, Switzerland – Tangerang, Indonesia (ots) - Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, ...
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research –Dr. Shumpei Ishikawa and ...
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...
Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...
Lausanne, Switzerland (ots/PRNewswire) - - Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists - The program launches the Galderma Excellence in Multichannel Medical Education (GEMME) platform, demonstrating ...
Lausanne, Switzerland (ots/PRNewswire) - - Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition - #RosaceaUnmasked encourages rosacea sufferers to speak with a doctor or dermatologist about the burden of regular ...
Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...